Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Predicts Humira Will Become $1 Bil. Product In 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

Adalimumab continues to eat away at Enbrel’s share of the self-injectable rheumatoid arthritis market, accounting for 27% of new prescriptions, up 2.5 points from December, Abbott says.

You may also be interested in...



Celebrex Label Adds Cardiovascular Risk Language

Celecoxib labeling revision includes long-term safety data from three celecoxib trials, one of which suggests increased cardiovascular risk. Celebrex also gains ankylosing spondylitis indication.

Celebrex Label Adds Cardiovascular Risk Language

Celecoxib labeling revision includes long-term safety data from three celecoxib trials, one of which suggests increased cardiovascular risk. Celebrex also gains ankylosing spondylitis indication.

Enbrel Maxing Out: Wyeth Sees Sales At Top End Of Forecast

Wyeth is "more confident than ever" that Enbrel will be "category leader" for TNF inhibitors, firm says. Enbrel on track for about $1.8 bil. in revenues this year.

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel